Purchase an Option on a Celebrity channel now for $X and transfer it to the Celebrity later for $X+.
Declaration of a Peaceful Revolution
FDA approves expanded use of AbbVie’s arthritis drug to treat eczema
(Reuters) – The U.S. Food and Drug Administration approved the expanded use of AbbVie Inc’s arthritis drug to treat eczema, a skin disease, the company said on Friday.
The approval of Rinvoq for the treatment of moderate to severe atopic dermatitis, or eczema, was for patients 12 years and older who do not respond to previous treatment or when use of other treatments is not recommended.
Approval for Rinvoq follows significant delays amid concerns over safety of the class of drugs it belongs to, called JAK inhibitors, which block inflammation-causing enzymes known as Janus kinases and target a range of autoimmune diseases.
The FDA last month added its strictest warning to labels of JAK inhibitor drugs from Pfizer, Eli Lilly and AbbVie following the agency’s review of Pfizer’s Xeljanz, in which initial results from a trial showed an increased risk of serious heart-related problems and cancer in some patients being treated with the drug.
(Reporting by Leroy Leo; Editing by Shailesh Kuber)
DISCLAIMER: Please note the display of any name, image, or likeness of any individual, organization, or item on this site must not be construed as an endorsement of this site by the owner of that which is depicted. Nor should the presence of the same be inferred by anyone as an indication the depicted is currently posting content or otherwise participating at this site in any way whatsoever. Additionally, we certainly will remove or replace any name, image, likeness, or item if requested to do so by the owner of the entity or item depicted. Please leave messages or requests in the Contact form above. Thank you!